Serum carboxymethyl-lysine, disability, and frailty in older persons

The cardiovascular health study

Heather E. Whitson, Alice M. Arnold, Laura M. Yee, Kenneth J. Mukamal, Jorge Kizer, Luc Djousse, Joachim H. Ix, David Siscovick, Russell P. Tracy, Stephen M. Thielke, Calvin Hirsch, Anne B. Newman, Susan Zieman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. Methods. In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. Results. Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. Conclusions. Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.

Original languageEnglish (US)
Pages (from-to)710-716
Number of pages7
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume69
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Health
Serum
Logistic Models
N(6)-carboxymethyllysine
Activities of Daily Living
Proportional Hazards Models
Geriatrics
Arthritis
Biomarkers
Odds Ratio
Kidney
Mortality

Keywords

  • Biomarkers
  • Disablement process
  • Epidemiology
  • Frailty-Metabolism

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Serum carboxymethyl-lysine, disability, and frailty in older persons : The cardiovascular health study. / Whitson, Heather E.; Arnold, Alice M.; Yee, Laura M.; Mukamal, Kenneth J.; Kizer, Jorge; Djousse, Luc; Ix, Joachim H.; Siscovick, David; Tracy, Russell P.; Thielke, Stephen M.; Hirsch, Calvin; Newman, Anne B.; Zieman, Susan.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 69, No. 6, 2014, p. 710-716.

Research output: Contribution to journalArticle

Whitson, HE, Arnold, AM, Yee, LM, Mukamal, KJ, Kizer, J, Djousse, L, Ix, JH, Siscovick, D, Tracy, RP, Thielke, SM, Hirsch, C, Newman, AB & Zieman, S 2014, 'Serum carboxymethyl-lysine, disability, and frailty in older persons: The cardiovascular health study', Journals of Gerontology - Series A Biological Sciences and Medical Sciences, vol. 69, no. 6, pp. 710-716. https://doi.org/10.1093/gerona/glt155
Whitson, Heather E. ; Arnold, Alice M. ; Yee, Laura M. ; Mukamal, Kenneth J. ; Kizer, Jorge ; Djousse, Luc ; Ix, Joachim H. ; Siscovick, David ; Tracy, Russell P. ; Thielke, Stephen M. ; Hirsch, Calvin ; Newman, Anne B. ; Zieman, Susan. / Serum carboxymethyl-lysine, disability, and frailty in older persons : The cardiovascular health study. In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences. 2014 ; Vol. 69, No. 6. pp. 710-716.
@article{113be6fa62fe47d28ee38975aad9489b,
title = "Serum carboxymethyl-lysine, disability, and frailty in older persons: The cardiovascular health study",
abstract = "Background. Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. Methods. In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. Results. Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95{\%} CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95{\%} CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. Conclusions. Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.",
keywords = "Biomarkers, Disablement process, Epidemiology, Frailty-Metabolism",
author = "Whitson, {Heather E.} and Arnold, {Alice M.} and Yee, {Laura M.} and Mukamal, {Kenneth J.} and Jorge Kizer and Luc Djousse and Ix, {Joachim H.} and David Siscovick and Tracy, {Russell P.} and Thielke, {Stephen M.} and Calvin Hirsch and Newman, {Anne B.} and Susan Zieman",
year = "2014",
doi = "10.1093/gerona/glt155",
language = "English (US)",
volume = "69",
pages = "710--716",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Serum carboxymethyl-lysine, disability, and frailty in older persons

T2 - The cardiovascular health study

AU - Whitson, Heather E.

AU - Arnold, Alice M.

AU - Yee, Laura M.

AU - Mukamal, Kenneth J.

AU - Kizer, Jorge

AU - Djousse, Luc

AU - Ix, Joachim H.

AU - Siscovick, David

AU - Tracy, Russell P.

AU - Thielke, Stephen M.

AU - Hirsch, Calvin

AU - Newman, Anne B.

AU - Zieman, Susan

PY - 2014

Y1 - 2014

N2 - Background. Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. Methods. In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. Results. Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. Conclusions. Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.

AB - Background. Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. Methods. In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. Results. Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. Conclusions. Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.

KW - Biomarkers

KW - Disablement process

KW - Epidemiology

KW - Frailty-Metabolism

UR - http://www.scopus.com/inward/record.url?scp=84901024965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901024965&partnerID=8YFLogxK

U2 - 10.1093/gerona/glt155

DO - 10.1093/gerona/glt155

M3 - Article

VL - 69

SP - 710

EP - 716

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 6

ER -